Mark Fulton, PhD

Mark Fulton, PhD, manages and supports several strategic alliances across several different research areas of interest and indications. Prior to joining Mass General Brigham, he was a consultant, working to help develop pharmaceutical strategy and support clinical decision-making. He earned his PhD from Vanderbilt University in the laboratory of Craig Lindsley, PhD, working to develop small molecules to probe the function of a unique receptor in the brain to better understand its function and potential as a drug target. He then went on to complete postdoctoral training at Harvard University with Matthe Shair, PhD, working across several projects, focused on developing small molecules for the treatment of several cancers.